BIOMARCADORES PARA DIAGNÓSTICO DE ENFERMEDAD INFLAMATORIA INTESTINAL

VolverVolver

Resultados 44 resultados LastUpdate Última actualización 19/10/2021 [22:21:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days



Página1 de 2 nextPage   por página


LIPOCALIN-2 ASSAY FOR INTESTINAL ADAPTATION

NºPublicación: WO2021207725A1 14/10/2021

Solicitante:

UNIV JOHNS HOPKINS [US]

Resumen de: WO2021207725A1

The present invention relates to the field of short bowel syndrome. More specifically, the present invention provides methods and compositions useful for assaying for intestinal adaptation. In a specific embodiment, a method for treating a patient having SBS who is undergoing parenteral nutrition comprises the steps of (a) measuring lipocalin-2 (LCN2) in a sample obtained from the patient; and (b) reducing or eliminating parenteral nutrition if the measured level of LCN2 is below a control level or treating the patient with IL-22, a LCN2 inhibitor and/or an AHR agonist if the measured level of LCN2 is above the control level.

traducir

METHODS AND TREATMENT INVOLVING EXCESS FREE LIGHT

NºPublicación: WO2021202649A2 07/10/2021

Solicitante:

AEVI GENOMIC MEDICINE LLC [US]

Resumen de: WO2021202649A2

The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.

traducir

MICROBIOME-BASED THERAPEUTICS

NºPublicación: WO2021195636A1 30/09/2021

Solicitante:

UNIV CORNELL [US]

Resumen de: WO2021195636A1

Provided herein is a method of treating an individual afflicted with an inflammatory bowel disease utilizing Candida abundance as a biomarker of responsiveness. The method comprises determining levels of Candida in a sample from the gastrointestinal tract of an individual, and if the level of Candida is higher than a reference level, identifying the individual as suitable for microbiota transplantation therapy (MTT), and optionally, administering to such an individual the MTT, and in individuals having gastrointestinal tract Candida levels lower than a reference level, increasing the Candida levels prior to prior to administration of MTT.

traducir

PREDICTING A TREATMENT RESPONSE IN INFLAMMATORY BOWEL DISEASE

NºPublicación: EP3884276A2 29/09/2021

Solicitante:

UNIV LEUVEN KATH [BE]

WO_2020104705_A2

Resumen de: WO2020104705A2

In general the present invention concerns a method for predicting the therapeutic outcome of a treatment of in inflammatory bowel disease for anti-TNF agents, anti- α4β7-intcgrin agents and/or anti- IL-12/23 agents. The method defines which the agents are likely to provide the best healing effect for a particular patients affected by an inflammatory bowel disease. In particular the method predicts the therapeutic outcome of a treatment of anti-TNF agents in inflammatory bowel disease.

traducir

METHODS AND COMPOSITIONS FOR PREDICTION OF RESPONSE TO A THERAPY OF AN INFLAMMATORY BOWEL DISEASE

NºPublicación: EP3880836A1 22/09/2021

Solicitante:

JANSSEN BIOTECH INC [US]

EA_202191354_A1

Resumen de: WO2020102519A1

Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.

traducir

TARGETED HD5 ANTIBODY AND ASSAY METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE

NºPublicación: US2021278417A1 09/09/2021

Solicitante:

MEHARRY MEDICAL COLLEGE [US]

CN_111032053_A

Resumen de: US2021278417A1

A targeted DEFA5 antibody is disclosed herein. The targeted DEFA5 antibody has a high degree of specificity with DEFA5 protein, particularly with peptide sequences of the P, B, and/or M binding sites of the DEFA5 protein. The targeted DEFA5 antibody may be incorporated into an assay for diagnosing and treating ulcerative colitis and Crohns disease in a subject suffering from inflammatory bowel disease. The assay may be provided in a kit. The targeted DEFA5 antibody may be used in a method for measuring the level of DEFA5 or DEFA5 expression in a sample collected from a subject, and determining, based on the level of DEFA5 or DEFA5 expression, whether the subject is suffering from ulcerative colitis or Crohns disease. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohns disease.

traducir

VARIANTS OF TNFSF15 AND DCR3 ASSOCIATED WITH CROHN'S DISEASE

NºPublicación: KR20210107176A 31/08/2021

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

JP_2020127437_A

Resumen de: WO2014186750A2

Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.

traducir

COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE

NºPublicación: US2021261651A1 26/08/2021

Solicitante:

ARTIZAN BIOSCIENCES [US]

BR_112021000025_A2

Resumen de: US2021261651A1

Described are compositions and methods for treating inflammatory bowel diseases in a subject in need thereof. In certain aspects, the disclosure provides methods of treating a subject diagnosed with Irritable Bowel Disease (IBD), the method comprising administering to the subject an agent to reduce the number or pathogenic effects of a B. fragilis strain, wherein the subject is diagnosed with IBD by detecting the presence of the B. fragilis strain or a B. fragilis toxin in a biological sample of the patient.

traducir

USE OF MUCOSAL TRANSCRIPTOMES FOR ASSESSING SEVERITY OF ULCERATIVE COLITIS AND RESPONSIVENESS TO TREATMENT

NºPublicación: EP3867399A1 25/08/2021

Solicitante:

CHILDRENS HOSPITAL MED CT [US]

CA_3116005_PA

Resumen de: WO2020082011A1

The present disclosure provides methods for assessing responsiveness or non- responsiveness to a therapeutic agent (e.g., steroid therapy, anti-TNF therapy or anti-integrin α4β7 therapy) in ulcerative colitis (UC) subjects based on gene signatures. The methods may further comprise identifying suitable treatment for the patient based on the gene signatures.

traducir

METHODS OF TREATING AND DIAGNOSING INFLAMMATORY BOWEL DISEASE

NºPublicación: EP3866793A1 25/08/2021

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

WO_2020081186_PA

Resumen de: WO2020081186A1

Described herein are methods of treatment of an inflammatory condition related to fungal immunity. The present disclosure relates to methods and systems for identifying patients suitable for treatment with active agents, as described herein. Further, described herein are various compositions for treating and identifying a subject in need of an active agent for treatment.

traducir

SYSTEMS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE THROUGH PERIPHERAL NERVE STIMULATION

NºPublicación: US2021252278A1 19/08/2021

Solicitante:

CALA HEALTH INC [US]

WO_2019143790_PA

Resumen de: US2021252278A1

Systems and methods for treating symptoms of an inflammatory gastrointestinal disease in a patient with transcutaneous stimulation of a peripheral nerve are disclosed. The method can include any number of positioning a first peripheral nerve effector on the patient's skin to stimulate the peripheral nerve of the patient, delivering a first electrical nerve stimulation signal transcutaneously to the peripheral nerve through the first peripheral nerve effector, and modifying at least one brain or spinal cord autonomic feedback loop relating to release of neurotransmitters from the autonomic nervous system that modulate synthesis of inflammatory biomarkers and reduce inflammation relating to the inflammatory gastrointestinal disease.

traducir

HUMAN THYMUS STROMAL LYMPHOPOIETIN MONOCLONAL ANTIBODY AND APPLICATION THEREOF

NºPublicación: WO2021155861A1 12/08/2021

Solicitante:

IPHASE THERAPEUTICS LTD [CN]

CN_111196850_A

Resumen de: WO2021155861A1

The present invention provides a human thymus stromal lymphopoietin (TSLP) monoclonal antibody and an application thereof. The TSLP antibody provided in the present invention can specifically bind to hTSLP, has high affinity, and can effectively inhibit the combination of TSLP and a receptor thereof so as to inhibit activation of a downstream signal path and activation of immune cells by TSLP. The TSLP antibody has great significance in content measurement of hTSLP and diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as allergic asthma, chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic nasosinusitis, eosinophilic granulocytic esophagitis, allergic conjunctivitis, inflammatory bowel disease or atopic dermatitis.

traducir

TEST AND IN VITRO DIAGNOSIS OF IRRITABLE BOWEL SYNDROME

NºPublicación: WO2021151942A1 05/08/2021

Solicitante:

IMMUNDIAGNOSTIK AG [DE]

Resumen de: WO2021151942A1

In vitro method for determining the type and severity of a gastrointestinal disorder in a subject suspected of suffering irritable bowel syndrome (IBS), comprising the steps of a) performing an assay method for detecting the presence of γ-tryptase in a fecal sample obtained from said patient; b) measuring the concentration of γ-tryptase in said fecal sample; c) comparing said measured concentration of γ-tryptase to a first predetermined reference value; and d) assessing of said patient by assigning an increased likelihood of suffering irritable bowel syndrome (IBS) when said measured concentration of γ-tryptase is higher than said predetermined reference value, or by assigning a decreased likelihood of suffering irritable bowel syndrome (IBS) when said measured concentration of γ-tryptase is lower than said predetermined reference value.

traducir

METHODS AND SYSTEMS FOR SELECTION AND TREATMENT OF PATIENTS WITH INFLAMMATORY DISEASES

NºPublicación: US2021238684A1 05/08/2021

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]
PROMETHEUS BIOSCIENCES INC [US]

KR_20210013062_A

Resumen de: US2021238684A1

Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohns disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.

traducir

SECOND GENERATION SEQUENCING-BASED METHOD FOR DETECTING MICROSATELLITE STABILITY AND GENOME CHANGES BY MEANS OF PLASMA

NºPublicación: EP3859010A1 04/08/2021

Solicitante:

GUANGZHOU BURNING ROCK DX CO LTD [CN]

BR_112021005966_A2

Resumen de: EP3859010A1

In one aspect, the present disclosure relates to a panel of biomarkers, a kit for detecting it, and its use in the detection of micro satellite instability (MSI) as well as non-invasive diagnosis, prognostic evaluation, selection of treatment or genetic screening of cancer, preferably colorectal cancer (such as bowel cancer), gastric cancer or endometrial cancer in a plasma sample. On the other hand, the present disclosure provides a method for detecting microsatellite instability (MSI) and disease-related gene mutations through plasma based on next-generation sequencing, and a device for implementing the method, especially the use of such detection method in the non-invasive diagnosis, prognostic evaluation, selection of treatment or genetic screening of patients with cancer, preferably colorectal cancer (such as bowel cancer), gastric cancer or endometrial cancer. This disclosure provides a plasma MSI detection method for the first time, which can determine the microsatellite instability of a sample with high accuracy and sensitivity.

traducir

Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

NºPublicación: NZ717633A 30/07/2021

Solicitante:

CEDARS SINAI MEDICAL CENTER

AU_2020203468_A1

Resumen de: NZ717633A

The present invention describes methods diagnosing irritable bowel syndrome (IBS) and distinguising IBS from inflammatory bowel disease (IBD) when anti-vinculin anitibody level is determined higher than anti-CdtB antibody level in a biological sample from a subject.

traducir

Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease

NºPublicación: NZ730490A 30/07/2021

Solicitante:

CEDARS SINAI MEDICAL CENTER

US_2019187153_A1

Resumen de: NZ730490A

Described herein are methods and systems for distinguishing diarrhea predominant irritable bowel syndrome (D-IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-vinculin antibodies and anti-CdtB antibodies to distinguish IBS from IBD and celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.

traducir

METHODS FOR PROGNOSING CROHN'S DISEASE COMPRISING HUMAN DEFENSIN 5 (HD5)

NºPublicación: US2021223265A1 22/07/2021

Solicitante:

STAPPENBECK THADDEUS [US]
LIU TA CHIANG [US]
VANDUSSEN KELLI [US]
UNIV WASHINGTON [US]

WO_2017189846_A1

Resumen de: US2021223265A1

The present disclosure provides methods for classifying a cell as abnormal based on HD5 protein detection as well as methods for predicting prognosis of a subject with Crohn's disease based on HD5 protein detection.

traducir

METHOD FOR INHIBITING STAT3 ACTIVITY

NºPublicación: US2021220447A1 22/07/2021

Solicitante:

CUROGEN TECH CO LTD [KR]

US_2018140681_A1

Resumen de: US2021220447A1

The present disclosure relates to a method for inhibiting a STAT3 activity, and a method for treating inflammatory bowel disease (IBD).

traducir

ANTI-MAA IMMUNOGLOBULIN ISOTYPES IN INFLAMMATORY BOWEL DISEASE: DIAGNOSTIC IMPLICATIONS FOR ULCERATIVE COLITIS

NºPublicación: WO2021146562A1 22/07/2021

Solicitante:

UNIV NEBRASKA [US]
AHMAD RIZWAN [US]

Resumen de: WO2021146562A1

In various embodiments methods of distinguishing Crohn's disease from ulcerative colitis are provided. In certain embodiments the methods comprise determining, or causing to be determined, the level of IgG antibodies that bind a malondialdehyde-acetaldehyde adduct (MAA adduct) in a biological sample from a mammal, where an elevated level of said antibodies as compared to the average level found in a mammal with Crohn's disease is an indicator that the mammal has ulcerative colitis rather than Crohn's disease.

traducir

METHODS AND COMPOSITIONS FOR TREATING ULCERATIVE COLITIS

NºPublicación: WO2021146644A1 22/07/2021

Solicitante:

SECOND GENOME INC [US]
RAVICHANDAR JAYAMARY DIVYA [US]
HAN ANDREW WONHEE [US]
DESANTIS TODD ZACHARY [US]
CHOW CHERYL EMILIANE T [US]

Resumen de: WO2021146644A1

Methods and compositions are provided herein for treating and/or diagnosing ulcerative colitis in a subject, using one or more bacterial strains such as Bacillus sp. BT1B_CT2, Bacteroides coprocola M16, Bacteroides eggerthii CCUG 9559, Bacteroides vulgatus 8482, Butyricimonas virosa MT12, Coprococcus eutactus ATCC 27759, Desulfovibrio piger DSM 749, Dolosigranulum pigrum IFO 15550, Eubacterium biforme DSM 3989, Eubacterium eligens DSM 3376, Fusobacterium.prausnitzii ATCC 27768, Howardella ureilytica GPC 589, Megasphaera elsdenii LC1, Parabacteroides johnsonii M-165, Phascolarctobacterium sp. YIT 12067, Roseburia hominus A2-183, or Ruminococcus callidus VPI 57-31.

traducir

DIAGNOSIS, PROGNOSIS AND TREATMENT OF A DISEASE RELATED TO A DECREASE OF F. PRAUSNITZII

NºPublicación: US2021215676A1 15/07/2021

Solicitante:

INST NAT SANTE RECH MED [FR]
CENTRE NAT RECH SCIENT [FR]
UNIV ANGERS [FR]
UNIV NANTES [FR]
HOPITAUX PARIS ASSIST PUBLIQUE [FR]
UNIV SORBONNE [FR]

WO_2019229247_A1

Resumen de: US2021215676A1

The invention relates to a method comprising a step of determining the number, concentration and/or proportion of T lymphocytes with a CD4+ CD8ααlow phenotype and further expressing CCR6 and/or CXCR6, for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing a disease related to a decrease of F. prau. The invention also concerns the treatment of said disease by administering a population of these specific T lymphocytes. The Inventors have indeed identified two markers, CCR6 and CXCR6, enabling to select a population of F. prau-specific cells among CD4+ CD8ααlow T lymphocytes, from a blood sample and without needing to assess their F. prauspecificity. T lymphocytes with a CD4+ CD8ααlow CCR6+ CXCR6+ phenotype are for example significantly decreased in IBD patients. The disease related to a decrease of F. prauis particularly an inflammatory bowel disease (IBD), such as Crohn's disease.

traducir

METHODS OF TREATING DISEASES

NºPublicación: EP3848390A1 14/07/2021

Solicitante:

BOEHRINGER INGELHEIM INT [DE]

US_2020299378_A1

Resumen de: EP3848390A1

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.

traducir

Method for assessmenting microbiome from Patients with inflammatory bowel disease

NºPublicación: KR20210087243A 12/07/2021

Solicitante:

UNIV INJE IND ACAD COOP FOUND [KR]

Resumen de: KR20210087243A

본 발명은 장 용종 절제술에 사용되는 인젝터를 흡인 카테터로 사용하여 대장 내시경 세척액을 흡인함으로써 염증성 장질환 환자의 미생물 군집을 평가하는 방법에 관한 기술로, 본 발명의 방법은 채취, 검사, 분석 등에 단점이 있는 기존 대변 채취 방법을 대체할 수 있고, 특히 대변은 장내 미생물의 최종 산물로 실제 장내에 존재하는 미생물 군집과 차이가 있는 바, 정확한 미생물 군집의 평가 방법을 제공한다는 점에서 이점이 있다.

traducir

DNA METHYLATION BASED BIOMARKERS FOR IRRITABLE BOWEL SYNDROME AND INFLAMMATORY BOWEL DISEASE

Nº publicación: US2021207217A1 08/07/2021

Solicitante:

UNIV CALIFORNIA [US]

WO_2019232468_PA

Resumen de: US2021207217A1

Methods, kits, devices, and materials described herein provide blood-based diagnostic, prognostic, and treatment-monitoring biomarkers for IBS and IBD. These biomarkers can be used to distinguish IBS and/or IBD patients from healthy controls, for example, as well as to distinguish between IBS and IBD or other related disorders.

traducir

Página1 de 2 nextPage por página

punteroimgVolver